0
Products in the cart
Total:
Information block example
Currency
English Support
Request a call
Working hours:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00

Erlonat 100mg

Erlonat 100mg (Erlotinib)

Erlonat tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.

Feature
Brand name:
Erlonat
Active substance:
Erlotinib 100mg
Manufacturer:
Natco Pharma Ltd.,
Packaging:
30 Tablets
Product form:
Tablet
In stock
Active substance: Erlotinib
0 $
Available options:
Amount:
To wishlist
Compared
Consulting:+91(994)0472902
Description

DESCRIPTION

Erlonat tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.

Erlonat tablets are prescription medicine, used only by the patients who have valid prescription

INDICATION

Erlonat is primarily indicated for; Non small cell lung cancer: Erlonat is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat is involved in the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlonat is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat is used in combination with gemcitabine. In this condition Erlonat is involved as first line treatment.

PHARMACOLOGY

Erlonat has pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factor receptor. This EGFR is occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

ADME PROPERTY

ABSORPTION

The peak plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its bioavailability to 100%. The Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlonat , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

Volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%.

METABOLISM

The metabolism of Erlotinib is occurs by CYP3A4

ELIMINATION

The route of elimination of Erlotinib metabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

DOSAGE MANAGEMENT

DOSAGE MANAGEMENT

In NSCLC: The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat is 100mg should be taken as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlonat therapy In severe hepatic failure: Stop the therapy permanently

In renal impairment: Discontinue the Erlonat therapy permanently In gastrointestinal perforation and severe diarrhea: Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive measures In corneal perforation, therapy should be discontinuing permanently. Avoid concomitant use of Erlonat with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SIDE EFFECTS

SOME SERIOUS ADVERSE EFFECT

Renal failure Liver toxicity with failure Gastrointestinal perforations Ocular disorders Hemorrhage Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

SOME COMMON SIDE EFFECTS

Rash Diarrhea Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Chest pain, arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while combining with lipid lowering drugs

DRUG INTERACTION

CYP3A4 INHIBITORS:
Concomitant use of Erlonat with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlonat .

IN CYP3A4 INDUCERS:
In combination of Erlonat with CYP3A4 inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeutic effect of Erlonat .

CYP1A2 INDUCERS & CIGARETTE SMOKING:
Both are decreasing the exposure of Erlotinib, while concomitant with Erlonat .

GASTRIC REGULATORS:
While concomitant with gastric regulators like proton pump inhibitors, H2 receptors antagonist or antacids, causes depletion of Erlotinib exposure leads to loss of therapeutic effect of Erlotinib.

ANTICOAGULANTS:
In combination of Erlonat with warfarin, causes increasing international normalized ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

PRECAUTION

In interstitial lung disease: Severe pulmonary toxicity occurs, this may prevent by discontinue the therapy with Erlonat . Renal failure: To prevent this problem, patients should be monitored periodically with renal function test. On the other hand stop the therapy with Erlonat . Hepatic failure: Liver function test should be taken and monitored the patients frequently for any obstruction in liver functions. To avoid this complication, withhold or discontinue the therapy with Erlonat

In GI perforation: This condition occurs due to concomitant use of Erlonat with NSAIDS, taxane based chemotherapy agents, anti-angiogenic drugs, or corticosteroids etc. This is prevent by avoiding these combinations, or stop the treatment with Erlonat . Hemorrhage: To monitor the patient prothrombin time and INR during the therapy. This condition is majorly occurred due to combination of Erlonat with warfarin. Avoid this concomitant. Erlonat is not recommended in pregnancy period, this results as embryo fetal damage.

PREGNANCY & LACTATION

The pregnancy category of Erlotinib is D Erlonat tablets are not recommended for pregnancy conditions, because it may cause fetal harm even to death. Breast feeding should not be recommended.

CONTRAINDICATION

No contraindication occurs during Erlonat therapy. Some hypersensitivity reactions occur due to ingredients of Erlonat is contraindicated to the patients.

STORAGE

Erlonat should be stored at 25°C (77°F). Erlonat tablets should be keeping away from heat, light & moisture.

OVER DOSAGE

The over dosage of Erlonat is not possible in all conditions. If it may occurs, postpone or discontinue the Erlonat therapy and provide the patients with symptomatic therapy

MISSED DOSE

Erlonat is a chemo medicine, prescribed by medical oncologist. If patients fail to take the dose of Erlonat tablet, consult with physician and follow the instructions. On the other hand, the missed dose should be skipped and follow the regular dosing schedule.

Feature
Brand name
Erlonat
Active substance
Erlotinib 100mg
Manufacturer
Natco Pharma Ltd.,
Packaging
30 Tablets
Product form
Tablet
Strength
100mg
Erlonat 100mg отзывы
Add a comment
0

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educati
MEDICAL DISCLAIMERAll the contents present on the website are solely for informational purposes. Thereby, the information on the website isn’t meant to be a substitute for professional medical advice, treatment, and/or diagnosis. Please seek professiona